Obermatt
See Similar Stocks →

Wave Life Sciences

NMQ:WVE · SG9999014716
PharmaceuticalsSmall

360

20
Profit price78
Owner Earnings Yield1
Dividend Yield1
Price/Sales8
Price/Book16
Return on Capital7
Cash Return on Capital10
Return on Equity8
EBIT Margin1
Gross Profitability6
Accruals50
Owner Earnings Margin9
Sales growth92
Profit Growth1
Long-Term EPS Growth1
Reinvestment74
Price momentum33
Debt load89
Refinancing4
Debt Payback1
Liquidity48
Analyst ratings78
Opinion Changes50
Price Target Upside98
Market mood91
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Wave Life Sciences doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountrySingapore
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2012
Websitewavelifesciences.com
ISINSG9999014716
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
NeurologyObesityStem Cell TherapyGeneticsNeuroscienceGenetic DisorderCentral Nervous SystemHepatologyBiotechnologyHealth CareScience and Engineering

Description

Wave Life Sciences Ltd. (‘Wave’), a clinical-stage biotechnology company, focuses on unlocking the broad potential of ribonucleic acid (‘RNA’) medicines (also known as oligonucleotides), or those targeting RNA, to transform human health. The company…

Analysis

Weak and unloved

Wave Life Sciences Ltd. is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 4/20 on our value-creation score: not creating value. Analysts lean positive.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
43
2023202420252026

All-time high

43

Jun 2026

All-time low

1

Jan 2025

Average rank

18

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
8
1
7
16
Price/Earnings
83
100
100
14
Price/Book
16
5
100
40
Dividend Yield
1
1
1
1
Value (overall)
16
10
30
19

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Wave Life Sciences with its peers
Belite Bio
NAQ:BLTE
49
CountryTaiwan
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Kyowa Hakko Kirin
TYO:4151
50
CountryJapan
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Panion & Bf Biotech
TAI:1760
84
CountryTaiwan
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Chunghwa Chemical Synthesis & Biotech
TAI:1762
13
CountryTaiwan
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Lotus Pharmaceutical
TAI:1795
19
CountryTaiwan
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
ScinoPharm
TAI:1789
25
CountryTaiwan
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →